Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRESCO-2: Fruquintinib in refractory metastatic colorectal cancer
NCT04322539Phase 3Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Aug 2020
- Primary completion
- Jul 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in metastatic colorectal cancer (mCRC) comparing Fruquintinib + BSC with Placebo + BSC (2 arms). Primary endpoint: Overall Survival up to 22 months. Started Aug 2020; status: completed.
02
Drugs
fruquintinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04322539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04322539.